152 related articles for article (PubMed ID: 35727143)
1. Switching from tenofovir alafenamide to tenofovir disoproxil fumarate improves lipid profile and protects from weight gain.
Kauppinen KJ; Aho I; Sutinen J
AIDS; 2022 Aug; 36(10):1337-1344. PubMed ID: 35727143
[TBL] [Abstract][Full Text] [Related]
2. Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study.
Surial B; Mugglin C; Calmy A; Cavassini M; Günthard HF; Stöckle M; Bernasconi E; Schmid P; Tarr PE; Furrer H; Ledergerber B; Wandeler G; Rauch A;
Ann Intern Med; 2021 Jun; 174(6):758-767. PubMed ID: 33721521
[TBL] [Abstract][Full Text] [Related]
3. Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV.
Plum PE; Maes N; Sauvage AS; Frippiat F; Meuris C; Uurlings F; Lecomte M; Léonard P; Paquot N; Fombellida K; Vaira D; Moutschen M; Darcis G
BMC Infect Dis; 2021 Sep; 21(1):910. PubMed ID: 34488664
[TBL] [Abstract][Full Text] [Related]
4. Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living with HIV: Lipid Changes and Statin Underutilization.
Brunet L; Mallon P; Fusco JS; Wohlfeiler MB; Prajapati G; Beyer A; Fusco GP
Clin Drug Investig; 2021 Nov; 41(11):955-965. PubMed ID: 34546533
[TBL] [Abstract][Full Text] [Related]
5. Weight changes in patients with sustained viral suppression switching tenofovir disoproxil fumarate to tenofovir alafenamide.
Schafer JJ; Zimmerman M; Walshe C; Cerankowski J; Shimada A; Keith SW
Obesity (Silver Spring); 2022 Jun; 30(6):1197-1204. PubMed ID: 35674696
[TBL] [Abstract][Full Text] [Related]
6. Reversible effect on lipids by switching from tenofovir disoproxil fumarate to tenofovir alafenamide and back.
Milinkovic A; Berger F; Arenas-Pinto A; Mauss S
AIDS; 2019 Dec; 33(15):2387-2391. PubMed ID: 31764103
[TBL] [Abstract][Full Text] [Related]
7. Comparison of weight gain after antiretroviral switch to integrase strand transfer inhibitor or tenofovir alafenamide-based therapy.
Sjaarda A; Bernstein A; Sparks A; Saber S; Siegel M
Infection; 2022 Apr; 50(2):407-412. PubMed ID: 34449049
[TBL] [Abstract][Full Text] [Related]
8. Weight gain before and after switch from TDF to TAF in a U.S. cohort study.
Mallon PW; Brunet L; Hsu RK; Fusco JS; Mounzer KC; Prajapati G; Beyer AP; Wohlfeiler MB; Fusco GP
J Int AIDS Soc; 2021 Apr; 24(4):e25702. PubMed ID: 33838004
[TBL] [Abstract][Full Text] [Related]
9. Switching tenofovir disoproxil fumarate to tenofovir alafenamide in a real life setting: what are the implications?
Schwarze-Zander C; Piduhn H; Boesecke C; Schlabe S; Stoffel-Wagner B; Wasmuth JC; Strassburg CP; Rockstroh JK
HIV Med; 2020 Jul; 21(6):378-385. PubMed ID: 32065713
[TBL] [Abstract][Full Text] [Related]
10. Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Significantly Worsens the Lipid Profile in a Real-World Setting.
Kauppinen KJ; Kivelä P; Sutinen J
AIDS Patient Care STDS; 2019 Dec; 33(12):500-506. PubMed ID: 31742421
[TBL] [Abstract][Full Text] [Related]
11. Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B.
Cheng PN; Feng IC; Chen JJ; Kuo HT; Lee PL; Yu ML; Chiu YC; Chiu HC; Chien SC; Chen PJ; Liu CJ
Aliment Pharmacol Ther; 2024 Jan; 59(2):230-238. PubMed ID: 37845815
[TBL] [Abstract][Full Text] [Related]
12. Brief Report: Effect of Antiretroviral Switch From Tenofovir Disoproxil fumarate to Tenofovir Alafenamide on Alanine Aminotransferase, Lipid Profiles, and Renal Function in HIV/HBV-Coinfected Individuals in a Nationwide Canadian Study.
Sarowar A; Coffin CS; Fung S; Wong A; Doucette K; Truong D; Conway B; Haylock-Jacobs S; Ramji A; Hansen BE; Janssen HLA; Cooper C
J Acquir Immune Defic Syndr; 2022 Dec; 91(4):368-372. PubMed ID: 36288543
[TBL] [Abstract][Full Text] [Related]
13. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine.
Cid-Silva P; Fernández-Bargiela N; Margusino-Framiñán L; Balboa-Barreiro V; Mena-De-Cea Á; López-Calvo S; Vázquez-Rodríguez P; Martín-Herranz I; Míguez-Rey E; Poveda E; Castro-Iglesias Á
Basic Clin Pharmacol Toxicol; 2019 Apr; 124(4):479-490. PubMed ID: 30388308
[TBL] [Abstract][Full Text] [Related]
14. Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B.
Suzuki K; Suda G; Yamamoto Y; Abiko S; Kinoshita K; Miyamoto S; Sugiura R; Kimura M; Maehara O; Yamada R; Kitagataya T; Shigesawa T; Ohara M; Kawagishi N; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N
PLoS One; 2022; 17(1):e0261760. PubMed ID: 35051189
[TBL] [Abstract][Full Text] [Related]
15. Outcomes associated with treatment change from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-1-infected patients: a real-world study in Japan.
Kanda N; Okamoto K; Okumura H; Mieno M; Sakashita K; Sasahara T; Hatakeyama S
HIV Med; 2021 Jul; 22(6):457-466. PubMed ID: 33720508
[TBL] [Abstract][Full Text] [Related]
16. Changes in Body Mass Index and Atherosclerotic Disease Risk Score After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide.
Schafer JJ; Sassa KN; O'Connor JR; Shimada A; Keith SW; DeSimone JA
Open Forum Infect Dis; 2019 Oct; 6(10):ofz414. PubMed ID: 31660372
[TBL] [Abstract][Full Text] [Related]
17. Weight and body mass index increase after switch from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate-containing treatment in an antiretroviral therapy-experienced group.
Łomiak M; Stępnicki J; Mikuła T; Wiercińska-Drapało A
Int J STD AIDS; 2021 May; 32(6):570-577. PubMed ID: 33612018
[TBL] [Abstract][Full Text] [Related]
18. Renal function change after switching tenofovir disoproxil fumarate for tenofovir alafenamide in the HIV-positive patients of a metropolitan sexual health service.
Turner D; Drak D; O'Connor CC; Templeton DJ; Gracey DM
AIDS Res Ther; 2019 Dec; 16(1):40. PubMed ID: 31810490
[TBL] [Abstract][Full Text] [Related]
19. Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate.
Huhn GD; Shamblaw DJ; Baril JG; Hsue PY; Mills BL; Nguyen-Cleary T; McCallister S; Das M
Open Forum Infect Dis; 2020 Jan; 7(1):ofz472. PubMed ID: 31950070
[TBL] [Abstract][Full Text] [Related]
20. Investigating the effect of antiretroviral switch to tenofovir alafenamide on lipid profiles in people living with HIV.
Lacey A; Savinelli S; Barco EA; Macken A; Cotter AG; Sheehan G; Lambert JS; Muldoon E; Feeney E; Mallon PW; Tinago W;
AIDS; 2020 Jul; 34(8):1161-1170. PubMed ID: 32310899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
